In patients with type 2 diabetes on diet and exercise or metformin, oral semaglutide significantly improved glycemic control (HbA1c reduction) and weight loss in a dose-dependent manner compared to placebo, with similar efficacy to subcutaneous semaglutide, though it was associated with higher rates of gastrointestinal side effects.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
CATEGORIES
© -2025 hormoneinsightc . all rights reserve.